Jennyfer Bultinck, PhD, is a molecular biologist in training with an extensive experience in conducting preclinical studies and validation of therapeutics. As a postdoctoral fellow at the École Polytechnique Fédérale de Lausanne, Switzerland, and later at VIB in Ghent, Belgium, she specialized in the validation of therapeutic targets in vivo and supervised the preclinical development of biologic drugs for the treatment of inflammatory and oncological diseases. Dr. Bultinck became an expert in the glucocerebrosidase enzyme and Gaucher disease since she started working at Oxyrane more than three years ago. Her fast professional growth goes hand in hand with the rapid advancement of Oxyrane's Gaucher disease program, underscoring her leadership, management and scientific skills. Since Parkinson's disease (PD) is not a core focus of Oxyrane, she chose to collaborate with Parkinson's experts, which will guarantee the proper execution of state-of-the-art research in this field.